Clinical OMICS

JUL-AUG 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1138741

Contents of this Issue

Navigation

Page 34 of 51

www.clinicalomics.com July/August 2019 Clinical OMICs 33 New Products BRAF Mutation Test Kits with 0.0001% Detection Sensitivity Cancer diagnostics company Genecast has launched of ADPS BRAF, EGFR, JAK2 mutation test kits with the highest detection sensitivity. Currently available for research use only (RUO), the ADPS BRAF mutation test kit has 0.0001% detection sensitivity, which the company says is 100 times higher than other prod- ucts available. Its EGFR and JAK2 mutation kits have detection sensitivity of 0.01%. The BRAF mutation test kit can diagnose four BRAF mutations found primarily in thyroid cancer and melanoma and since the ADPS technology is based on qPCR, it can reduce the expense and shorten clinical test time. Gene- cast plans to launch KRAS, NRAS, PIK3CA, pTERT, IDH1, and IDH2 mutation test kits (RUO) by the end of 2019, and complete cer- tification of CE-IVD for 9 Oncology kits by the first half of 2020. Genecast www.igenecast.com NGS-Based NIPT for Comprehensive Detection of Rare Chromosomal Conditions Illumina has launched VeriSeq NIPT Solution v2, a CE-IVD, an NGS-based approach to noninvasive prenatal testing (NIPT). The automated solution allows laboratories to screen for a broader range of chromosomal and sub-chromosomal conditions associated with birth de- fects and adverse pregnancy outcomes than the standard NIPT menu. VeriSeq NIPT Solution v2 provides accurate information about fetal chromosomal status as early as 10 weeks of gestation using a single maternal blood draw. This noninvasive test provides an option to screen for aneu- ploidy in all autosomes, chromosomes X & Y, and partial deletions and duplications greater than 7 Mb across the genome. Due to its high-sensitivity and high-specificity (low false-positive and false-negative rates), NGS-based NIPT minimizes the need for invasive testing procedures. The automated, solution provides reagents, instruments, installation and training, and allows labora- tories to process up to 96 samples in about one day. Illumina www.illumina.com Multi-Gene Liquid Biopsy Breast Cancer Panel Liquid biopsy test provid- er Biocept has announced Target Selector NGS Breast Panel, a multi-gene liquid biopsy panel specifically developed for breast cancer. The Target Selector NGS Breast Pan- el—which runs on Thermo Fisher Scientific's Ion Torrent NGS plat- form—combines Biocept's expertise in blood sample preservation and DNA/RNA isolation, with Thermo Fisher's NGS panel and its Oncomine informatics technology. Molecular profiling determines the status of actionable biomarkers such as ER, PR, and HER2 to guide clinicians in their treatment selection for women with breast cancer. The company's technology allows monitoring of biomark- er status in patients with metastatic breast cancer using the 12- gene Target Selector NGS Breast Panel, or the Target Selector sin- gle biomarker tests leveraging Biocept's proprietary circulating tumor DNA (ctDNA) or recently expanded circulating tumor cell (CTC) detection platforms. Biocept www.biocept.com Next-Generation Analytics for Cancer Treatment Decision Making Oncology Analytics announced the release of Oncology Insights, a next-generation analytics software solution that delivers current, rele- vant, and structured oncology data, supported by expert clinical advisory services. Oncology Insight leverage real-world data employing natural language processing to incorporate clinical notes, lab reports, radiology scan results, and chemotherapy regimen data. Compar- ative benchmarking provides HIPAA-compliant methods to de-identify the data to enable health plans to compare their performance against other similar organizations and its advisory services provides team of board-certified oncology pharmacists and clinical analysts, who help interpret the data and surface immediate actionable insights. This approach lessens health plans' burden of managing multiple data sources and ensures their focus on strategic areas that will have the greatest impact on their members. Oncology Analytics www.oncologyanalytics.com

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JUL-AUG 2019